Aby J. Mathew - 19 Jul 2021 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
Exec VP & Chief Scientific Off
Signature
/s/ Aby Mathew
Issuer symbol
BLFS
Transactions as of
19 Jul 2021
Net transactions value
-$811,410
Form type
4
Filing time
21 Jul 2021, 20:30:48 UTC
Previous filing
01 Jul 2021
Next filing
25 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $16,400 +10,000 +4.8% $1.64* 219,589 19 Jul 2021 Direct
transaction BLFS Common Stock Sale $438,500 -10,000 -4.6% $43.85 209,589 19 Jul 2021 Direct F1, F2
transaction BLFS Common Stock Options Exercise $14,521 +8,854 +4.2% $1.64* 218,443 21 Jul 2021 Direct
transaction BLFS Common Stock Sale $403,831 -8,854 -4.1% $45.61 209,589 21 Jul 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -10,000 -8.5% $0.000000 107,707 19 Jul 2021 Common Stock 10,000 $1.64 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -8,854 -8.2% $0.000000 98,853 21 Jul 2021 Common Stock 8,854 $1.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.43 to $44.52, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.14 to $46.03, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.